Tamtam Try Tamtam free
Sanofi logo

Sanofi account plan

AI-powered biopharma company

At a glance

Sanofi is a Paris-based biopharma company in immunology, rare diseases and vaccines, with €43,626m 2025 net sales led by Dupixent and 74,846 employees.

Sanofi is a Paris-based biopharma company that reports a single Biopharma segment run through Specialty Care, General Medicines and Vaccines, with research centred on immunology. It has business operations in about 60 countries, sells in more than 160 and ranks as the ninth-largest pharmaceutical company globally; the US was 50.8% of 2025 sales. FY2025 net sales were €43,626m (+9.9% at constant exchange rates), business operating income €12,149m and IFRS net income €7,813m, with Dupixent alone at €15,714m. Headcount was 74,846 at end-2025 after the consumer health business Opella was deconsolidated in April 2025; Sanofi keeps a 48.2% stake in it.

Business units

Strategic priorities

Maximise Dupixent
Dupixent is expected to reach around €25bn in 2030; a Defend, Extend, Innovate plan targets protection beyond the March 2031 US compound patent expiry, including four-weekly dosing.
Grow pharma launches
Pharma launches are targeted at about €10bn by 2030 and €5.2-5.3bn in 2026, led by ALTUVIIIO, Sarclisa, Ayvakit, Nexviazyme and Rezurock.
Fix R&D productivity
CEO Belén Garijo launched an outside-in portfolio review that has already cut amlitelimab, itepekimab and balinatunfib, and wants more scientific rigor in Phase 2-to-Phase 3 decisions.
Intensify business development and M&A
Sanofi could invest up to €15 billion in BD and M&A this year while keeping its AA rating, focusing on dermatology, respiratory and rare diseases; bigger deals are an option.
Regain momentum in China
Thomas Triomphe leads China from 1 September 2026, to sell into the market and in-license Chinese innovation.
AI-powered efficiency
The Plai decision platform is used by 22,000+ employees and the Concierge GenAI tool has 30,000 users; efficiency savings fund R&D.

Latest results

In H1 2026 net sales rose 15.7% at CER to €22,106m, driven by Dupixent (€9,324m, +34.4%), ALTUVIIIO and Ayvakit, while vaccines fell 1.1%. Business operating income grew 16.7% to €6,258m and business EPS 17.1% to €3.97, but IFRS net income fell to €1,957m after a €952m amlitelimab impairment and restructuring. In Q2 2026 Dupixent passed €5bn in a quarter for the first time, at €5,154m. Net debt rose to €15,513m after the Dynavax acquisition, the dividend and buybacks. Guidance was raised to around 10% sales growth at CER in 2026, with business EPS growing slightly faster.

Investments and deals

2025 acquisitions
Blueprint Medicines (~$9.1bn equity), Vicebio ($1.15bn upfront), Vigil Neuroscience (~$470m) and Dren-0201 (€539m upfront); acquisitions above €500m used €10,986m of cash.
Dynavax
Closed on 10 February 2026 for ~$2.2bn, adding the Heplisav-B hepatitis B vaccine and a shingles candidate.
US manufacturing commitment
Under the 19 December 2025 MFN agreement Sanofi reaffirmed a $20bn US manufacturing investment in exchange for a three-year tariff exemption.
Capex and buybacks
Capex of €1,762m in property, plant and equipment in 2025, with about €1.75bn a year expected in the medium term; a €1bn buyback was completed in April 2026.
Divestments
Opella's 50% controlling stake was sold to CD&R for €10.4bn net cash, Enjaymo went to Recordati, and the Brazilian generics unit Medley is being sold.

Challenges and risks

US drug pricing
The MFN agreement brings 61% price cuts on selected drugs and a $35 insulin cap, and the CMS GLOBE and GUARD models could have a material adverse effect.
Pipeline setbacks
Impairments on tolebrutinib (€1,663m) in 2025 and amlitelimab (€952m) in 2026, plus discontinued programmes, put R&D productivity under scrutiny.
Dupixent concentration
The group depends heavily on Dupixent, which faces the March 2031 US compound patent expiry; Regeneron profit-sharing reached €5,065m in 2025.
Weak vaccines and China
Vaccines are expected slightly negative in 2026 on weaker US vaccination rates, and China sales fell 3.5% in H1 2026 as fewer births hit paediatric vaccines.
Generic erosion and Regeneron reimbursement
Generic erosion cost €353m of sales in 2025, and the end of Regeneron development reimbursement leaves a €200m net BOI gap in 2027.

What leadership says

“My first months as CEO have focused on assessing the challenges facing Sanofi and working on an accelerated transformation roadmap that leverages our commercial strengths and focuses on the need for R&D and pipeline improvements”

Belén Garijo, Chief Executive Officer · Q2 2026 results press release, 30 July 2026

“It is also absolutely imperative that we intensify our business development and M&A activity in a disciplined way.”

Belén Garijo, Chief Executive Officer · Q2 2026 earnings call, 30 July 2026

“Our current focus is Dupixent, one. Two, Dupixent. Three, Dupixent.”

Belén Garijo, Chief Executive Officer · Q2 2026 earnings call, 30 July 2026

“take some time to make the right diagnostic”

Olivier Charmeil, Interim CEO and EVP General Medicines · Q1 2026 earnings call, 23 April 2026, advice to the incoming CEO

Where a supplier can help

Clinical operations and trial design
The push for R&D rigor and end-to-end clinical operations from study design to trial conclusion opens room for CROs, trial analytics and decision-support tools.
Licensing and BD support
Intensified BD and M&A, including in-licensing Chinese innovation, needs scientific due diligence, deal advisory and alliance management partners.
US manufacturing capacity
The reaffirmed $20bn US manufacturing investment points to demand for biologics plant engineering, equipment and contract manufacturing.
Market access and pricing analytics
MFN pricing, IRA negotiation and CMS models raise the need for gross-to-net, rebate and market access analytics.
AI and data platforms
Sanofi's AI-powered efficiency agenda, with Plai and GenAI tools in wide use, favours AI, data and automation providers across R&D and manufacturing.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Sanofi?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Sanofi

What does Sanofi do?

Sanofi develops, makes and sells medicines and vaccines in immunology, rare diseases, neurology, oncology and vaccines; Dupixent is its largest product.

What is Sanofi's revenue?

FY2025 net sales were €43,626m, up 9.9% at constant exchange rates; H1 2026 net sales were €22,106m.

How many employees does Sanofi have?

74,846 at end-2025, after the transfer of Opella staff.

Who is Sanofi's CEO?

Belén Garijo has been CEO since 1 May 2026, succeeding Paul Hudson; François-Xavier Roger is CFO.

What is Sanofi's strategy?

Grow Dupixent and new launches, fix R&D productivity through a portfolio review, intensify BD and M&A in its strongest disease areas and regain momentum in China.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)